Anti-Hypertension Drugs Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH469 | Last Updated On: Jul 05 2022 | Available Formats

> Global Anti-Hypertension Drugs Market Expected to reach a high CAGR By 2029: DataM Intelligence

Global Anti-Hypertension Drugs Market is segmented by Therapy Type (Calcium Channel Blockers, Diuretics, Beta Blockers Vasodilators, Angiotensin-Converting Enzyme Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Renin Inhibitors, Endothelin receptor antagonist, Prostacyclin Analogs, Phosphodiesterase inhibitors, sGC stimulators), By Drug Class (Systemic Hypertension, Pulmonary Arterial Hypertension), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.


Market Overview

The Global Anti-Hypertension Drugs Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Hypertension is a long-term medical condition that is marked by the high pressure of blood in the arteries, which is persistently elevated. Anti-hypertensive is used for the treatment of patients suffering from high blood pressure also known as hypertension. Hypertension is a major disorder accompanied by serious complications such as heart attack, heart failure, and dementia.

Market Dynamics

The global anti-hypertension drugs market growth is driven by the surge in the incidence of hypertension across the globe. Furthermore, a rise in awareness related to complications associated with hypertension is a major factor that fuels the growth of the market.

Growing initiatives by private and government organizations drive the market growth

The anti-hypertensive drugs market growth is driven by the growing initiatives by private and government organizations and rising awareness about hypertension around the around. For instance, in July 2020, Glenmark Pharmaceuticals launched the world’s first hypertension awareness symbol backed by the Association of Physicians of India (API) and Hypertension Society of India (HIS).

As per the updated May 2021 data from the World Health Organization, about 1.13 billion people around the world have hypertension, of which two-thirds are living in low- and middle-income countries. The report published in June 2020 titled “A Global View on Prevalence of Hypertension and Human Development Index” to determine the relationship between the prevalence of hypertension and human development index (HDI) concluded that the prevalence of hypertension ranged from 35 to 41% among 182 countries around the world. Thus, the rising additionally hypertension is expected to drive the growth of the anti-hypertensive drugs market.

Additionally, the development of imidazolines, monatepil, and neutral endopeptidase inhibitors are acting as other growth-inducing factors. These next-generation drugs cause minimal fatigue and dry mouth and can also aid in lowering blood pressure by inhibiting the metabolism of vasoactive peptides.

Side effects associated with the hypertension treatment to hamper growth

Factors such as the expiration of patent of multiple major drugs along with side effects associated with the hypertension treatment and rise in the availability of other non-pharmacological based therapy will restrict the growth of the anti-hypertensive drugs market. For instance, as per AbbVie, the parent company of Allergan, the patent of its anti-hypertensive drug, Bystolic (Nebivolol) is expiring in December 2021.

COVID-19 Impact Analysis

The COVID-19 pandemic had a severe impact on people with any kind of comorbidity including hypertension. Also, due to lockdown and other restrictions placed to curb the spread of the infection from the SARS-CoV-2 virus, the lifestyle of patients with hypertension was severely impacted. As per the July 2020 report from the American College of Cardiology, the early report from the COVID-19 hotspots like Wuhan, Lombardy, and New York City showed that people with hypertension were among the severely ill and hospitalized COVID-19 patients which in turn expected to boost the growth of the anti-hypertensive drugs market.

Segment Analysis

The diuretics segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)        

Diuretics help in reducing the sodium and water from the body by inducing kidneys to release more sodium into the urine which leads to lower blood pressure as fluid flowing through the body is decreases. Diuretics are the preferred class of therapeutic drugs for the treatment of hypertension over others mainly because of their high efficacy, low cost, and low chances of side effects as compared to other available therapeutic classes in the anti-hypertensive drugs market.

Diuretics are of three types - thiazide diuretics, loop diuretics, and potassium-sparing diuretics, from which thiazide diuretics are the cornerstone of treatment for hypertension in most patients around the world. For instance, as per the research article published in August 2019, titled “Redefining Diuretics Use in Hypertension: Why Select a Thiazide like Diuretic?”, diuretics are listed as first-line treatment options in the hypertension treatment guidelines throughout the world mainly due to their effectiveness in acting against the mechanism that causes high blood pressure.

Also, in the United States, the Joint National Committee on the prevention, detection, evaluation, and treatment of high blood pressure recommends thiazide-type diuretics to be one of the preferred drug treatments for hypertension, whether used on its own or along with other antihypertensive drugs, such as calcium channel blockers. Therefore, owing to the above-mentioned factors, the diuretics therapeutics class is expected to have the highest growth as compared to others with the rise in the prevalence of hypertension cases around the world.​

Geographical Analysis

North America region holds the largest market share of the Global Anti-Hypertension Drugs Market

North America holds a major share in the anti-hypertensive drugs market and is expected to show a similar trend over the forecast period mainly due to the high prevalence of hypertension and diseases causing hypertension in the region. Additionally, the demand for prompt and accurate diagnosis and treatment of hypertension, identifying people predisposed to the disease, presence of technically advanced healthcare infrastructure, and management of the prognosis of the disease are some of the key market drivers of the North American anti-hypertension drugs market.

In North America, the United States will hold the largest market in the anti-hypertensive drugs market in the region. In the United States, the rising prevalence of hypertension is the major reason for the growth of the anti-hypertensive drugs market. As per the April 2020 data of the National Center for Health Statistics, the prevalence of age-adjusted hypertension in the United States was 45.4% in adults and was 51% in men and 39.7% in women during the survey period of 2017-2018. Also, as per the report, the prevalence of hypertension decreased from 47% in 1999-2000 to 41.7% in 2013-2014, and then again increased to 45.4% in 2017-2018. The other factors such as increasing awareness among the people about hypertension and new product launches by the pharmaceutical companies in the region. For instance, in November 2018, Dr. Reddy’s Laboratories launched an anti-hypertensive drug, Chlorthalidone tablets in the United States market for the treatment of high blood pressure. Thus, North America is expected to hold a major market share in the anti-hypertensive market.

Competitive Landscape

The anti-hypertension drugs market is a moderately competitive presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include C.H. Boehringer Sohn AG & Ko. KG, Daiichi Sankyo Company Limited, Johnson & Johnson, Lupin Limited, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi SA among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Anti-Hypertension Drugs Market globally. For instance, In February 2021, Hanmi Pharmaceuticals announced the launch of a 4-ingredient drug combo for the treatment of hypertension and hyperlipidemia, called Amosartan XQ.

Pfizer Inc.


Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.    

Product Portfolio:

NORVASC:  NORVASC is a type of medicine known as a calcium channel blocker (CCB). It is used to treat high blood pressure (hypertension) and a type of chest pain called angina. It can be used by itself or with other medicines to treat these conditions.

Trending Topics

Clinical Trial Management System Market

Epidermolysis Bullosa Therapeutics Market\

Clinical Trial Management System Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!